News

Seattle Genetics has discontinued the SeaGen MARINER phase IIb clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of complete

Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that would develop vaccines for infectious diseases prevalent in

Santhera, a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, has closed the acquisition of Turku, Finland-based Oy Juvantia Pharma. The closing of the transaction triggers a

SRI International has acquired a $6.3m contract by the National Institute of Mental Health (NIMH) to conduct preclinical safety studies of ligands that will be used for brain

Depomed has reported top-line results from a phase 3 clinical trial of DM-1796, also referred to as gabapentin ER. It showed to achieve a significant reduction in pain

MediGene has received feedback from the UK MHRA (Medicines and Healthcare products Regulatory Agency) regarding the in-vitro studies conducted with the drug candidate RhuDex for the treatment of

Genentech, a wholly-owned member of the Roche Group, has reported results from two phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion

Sigma-Aldrich and Sangamo BioSciences have announced the expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified

Lupin has granted Salix Pharmaceuticals the exclusive US rights for its bioadhesive drug delivery technology for use with Rifaximin. Lupin and Salix have entered into an agreement under